Korean J Obstet Gynecol.  2005 Jun;48(6):1448-1455.

Clinical analysis of Paclitaxel and Platinum in Recurrent Carcinoma of the Uterine Cervix

• Jeon SW
• Ju YT
• Kim JH
• Ahn OJ
• Moon Y
• Lee KB
• Shin JW
• Lee JM
• Park CY

Abstract

OBJECTIVE
This study was performed to evaluate the efficacy and the toxicity of paclitaxel and platinum in patients with recurrent cervical carcinoma.
METHODS
Twenty nine patients were treated with paclitaxel 135-175 mg/m2 and cisplatin 50-75 mg/m2 or carboplatin at AUC 5 every 3 weeks for a maximum of six courses from January 2001 to January 2004.
RESULTS
A total 134 cycles with paclitaxel and platinum were administered. Ten patients (34.2%) achieved an objective response, including four complete responses (13.6%) and six partial responses (20.6%). Overall survival was 13.2 months, and the response and non-response group were 23.2 and 8.1 months, respectively (p=0.01). Clinical response according to recurrent site was significantly different (p=0.048) but, survival was not (p=0.22). Grade 3 or 4 granulocytopenia in 75.9% of patients was developed and one expired due to neutropenic sepsis after first cycle chemotherapy.
CONCLUSION
The combination of paclitaxel and platinum seems relatively well tolerated and has 34.2% response rate in patients with recurrent cervical cancer. Further study for this combination chemotherapy and prognostic factor should be needed.

Keyword

Recurrent; Cervical cancer; Paclitaxel; Platinum

MeSH Terms

Agranulocytosis
Area Under Curve
Carboplatin
Cervix Uteri*
Cisplatin
Drug Therapy
Drug Therapy, Combination
Female
Humans
Paclitaxel*
Platinum*
Sepsis
Uterine Cervical Neoplasms
Carboplatin
Cisplatin
Paclitaxel
Platinum